MP37-18 SOX2 IS ASSOCIATED WITH EXTRACAPSULAR EXTENSION FOLLOWING RADICAL PROSTATECTOMY FOR PROSTATE CANCER

Abstract

You have accessJournal of UrologyProstate Cancer: Basic Research I1 Apr 2015MP37-18 SOX2 IS ASSOCIATED WITH EXTRACAPSULAR EXTENSION FOLLOWING RADICAL PROSTATECTOMY FOR PROSTATE CANCER Blake Anderson, Steven Kregel, Gladell Paner, Gregory Zagaja, and Donald Vander Griend Blake AndersonBlake Anderson More articles by this author , Steven KregelSteven Kregel More articles by this author , Gladell PanerGladell Paner More articles by this author , Gregory ZagajaGregory Zagaja More articles by this author , and Donald Vander GriendDonald Vander Griend More articles by this author View All Author Informationhttps://doi.org/10.1016/j.juro.2015.02.1281AboutPDF ToolsAdd to favoritesDownload CitationsTrack CitationsPermissionsReprints ShareFacebookTwitterLinked InEmail INTRODUCTION AND OBJECTIVES The transcription factor Sox2 has been shown to promote castrate-resistant prostate cancer and may be associated with more aggressive tumors. Thus, Sox2 may correlate with worse surgical pathology and could be useful as a potential biomarker for predicting biochemical recurrence (BCR) after radical prostatectomy (RP) for prostate cancer (PCa). METHODS Using an institutional prostate cancer database with 3674 records, patients were identified with BCR after RP who met the inclusion criteria: ≤ T3a, NX or N0, Gleason 7 prostatic adenocarcinoma with negative margins, adequate PSA data and available pathology specimens. A control group with no evidence of disease (NED) was identified who met the same criteria but without BCR. The primary outcome was Sox2 positivity in PCa specimens, assessed with respect to tumor stage and BCR. Slides were stained with Sox2 antibody and positivity in tumor was determined independently by a genitourinary pathologist who was blinded to stage and BCR. Statistical tests performed were Chi-square and two sample t-tests. RESULTS 70 patients who underwent RP from 2003-2012 were enrolled in the study, with 34(49%) in the BCR group and 36 (51%) in the NED group. For the primary endpoints, Sox2 positivity was slightly higher in patients with BCR compared to those with NED, but this did not reach statistical significance (38% vs. 33%, p=0.67). However, in total, patients with T3a disease had significantly more Sox2 positivity than those with T2 tumors (50% vs. 25%, p=0.03). No significant differences were seen between BCR and NED groups in race, mean age at diagnosis (61.4 ± 6.9 vs. 58.8 ± 5.8, p=0.16), age at RP (62.1 ± 6.6 vs. 61.6 ± 6.3, p=0.26), BMI (27.7 ± 3.7 vs. 28.1 ± 4.4, p=0.71), preoperative PSA (6.5 ± 3.8 vs. 6.3 ± 3.0, p=0.84), Gleason score (primary: 3.38 ± 0.49 vs. 3.33 ± 0.48, p=0.67, secondary: 3.59 ± 0.5 vs. 3.67 ± 0.48, p=0.5), pathologic stage (59% T2, 41% T3a vs. 56% T2, 44% T3a, p=0.78), or months of follow-up (61 ± 23 vs. 55 ± 34, p=0.41). CONCLUSIONS In this study, Sox2 was found to be significantly associated with extracapsular extension on pathology from RP. Future studies with larger numbers of patients and other degrees of pathology will be helpful to further demonstrate the possible impact of Sox2 as a biomarker for BCR. © 2015 by American Urological Association Education and Research, Inc.FiguresReferencesRelatedDetails Volume 193Issue 4SApril 2015Page: e444 Advertisement Copyright & Permissions© 2015 by American Urological Association Education and Research, Inc.MetricsAuthor Information Blake Anderson More articles by this author Steven Kregel More articles by this author Gladell Paner More articles by this author Gregory Zagaja More articles by this author Donald Vander Griend More articles by this author Expand All Advertisement Advertisement PDF downloadLoading ...